Wuhan Hiteck Biological Pharma Co Ltd (300683) fair value: what the stock is really worth
As of Sep 30, 2026: fair value of Wuhan Hiteck Biological Pharma Co Ltd ¥6.22, price ¥25.54, upside -75.7%, quality 44 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 2, 2026.
How to read this chart
60‑month range ¥19.83 – ¥69.31 · fair‑value band ¥4.10 – ¥7.77 · the ¥25.54 price screens above the ¥6.22 fair value. Dashed = 300-day average. As of Oct 2, 2026.
Follow Wuhan Hiteck Biological Pharma Co in your weekly email
Every Wednesday you see whether Wuhan Hiteck Biological Pharma Co is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China.
Show more
Wuhan Hiteck Biological Pharma Co.,Ltd, a biopharmaceutical company, engages in the research and development, production, and sale of bio engineering products and freeze-dried powder injection in China. Its products include Epramine for injection; mouse nerve growth factor for injection; Anewway, a mouse nerve growth factor for injection; omeprazole sodium for injection, an alternative therapy for duodenal ulcer, gastric ulcer, reflux esophagitis, and Zollinger-Ellison syndrome; adenosine cyclophosphate for injection that is used for angina pectoris, myocardial infarction, myocarditis, and cardiogenic shock; aciclovir dispersible tablets for the treatment of genital herpes virus infection, herpes zoster, and immune deficiency chickenpox; Pentoxone theobromine injection; Roxatidine Acetate Hydrochloride for Injection; and Terizazole phosphate for injection. The company also provides measles and rubella virus nucleic acid detection kits; isolation and identification tubes and kits for mycoplasma; and bacterial vaginosis (BV) rapid test kits, as well as diagnostic kits for novel coronavirus N-Protein. In addition, it offers diagnostic kits for IgG antibody to measles virus, hydatid, toxoplasma, rubella virus, cytomegalo virus, and herpes simplex virus I/II; diagnostic kits for IgM antibody to measles virus, herpes simplex virus I/II, cytomegalo virus, rubella virus, and toxoplasma; and diagnostic kits for a "Thalassemia. Further, the company provides Lopinavir and Ritonavir APIs, and intermediates. It offers its products in the field of nervous system and oncology. Wuhan Hiteck Biological Pharma Co.,Ltd was founded in 1992 and is based in Wuhan, China.
Stock analysis
Wuhan Hiteck Biological Pharma Co Ltd (300683) currently trades at ¥25.54, while our model-based Fair Value estimate is ¥6.22, 75.7% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 94/100, which puts the evidence level at low.
Scenario range: ¥4.10 (bear) to ¥7.77 (bull), the price of ¥25.54 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.
Weak Growth: Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Wuhan Hiteck Biological Pharma Co Ltd reported revenue of 541M CNY in FY2025 versus 615M CNY in FY2021, a compound −3.1%/yr. Reported net income was −231M CNY in FY2025.
Key figures
Market cap 3.3B CNY (≈ $499M) · P/S ratio 6.80 · EPS (TTM) ¥−2.07 · Dividend yield 0.5% · Net margin −42.7% · Return on equity −12.4% · Return on assets (EBIT) −2.3% · Operating margin −108%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 48% below its 52-week high and 12% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −19% fair-value upside, at −76%, 300683 screens richer than that median.
Fair Value models
Bear ¥4.10Fair Value ¥6.22Bull ¥7.77
Price ¥25.54 · Upside -75.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Growth has flattened: the last year, three and five years all grew more slowly than the long-term average.
Revenue growth 1 year
−16.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−7.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.7%
Start year 2020 (pandemic). Over 10 years: −2.2% a year
Revenue growth 12 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+3.6%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6.7% (2020) → −22.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Wuhan Hiteck Biological Pharma Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 603 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−75.6% · Bottom 25%
Profitability
Return on assets−4.4% · Bottom 25%
Net margin (TTM)−55.1% · Bottom 25%
Operating margin (TTM)−107.7% · Bottom 25%
Growth and dividend
Revenue growth−43.9% · Bottom 25%
Dividend yield (TTM)0.5% · Bottom 25%
Balance sheet
Debt / equity0.01× · Lowest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B0.23× · Cheapest 25%
P/S (TTM)1.01× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 18
FUTURE (revenue growth)0· sector 24
PAST (return on equity)0· sector 27
HEALTH (low debt)100· sector 96
DIVIDEND (yield)11· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Wuhan Hiteck Biological Pharma Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/300683
Frequently asked questions
Is Wuhan Hiteck Biological Pharma Co Ltd (300683) overvalued or undervalued?
As of Oct 2, 2026, our model estimates a fair value of ¥6.22 versus the last price from Sep 30, 2026 of ¥25.54, about −76% upside (overvalued).
What is the fair value of 300683?
Our model-based fair value for Wuhan Hiteck Biological Pharma Co Ltd is ¥6.22 (as of Oct 2, 2026), built from audited fundamentals. Last price (from Sep 30, 2026): ¥25.54.
What is the quality score of 300683?
Wuhan Hiteck Biological Pharma Co Ltd has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Our model-based price target is the fair value of ¥6.22 (as of Oct 2, 2026) from 1 valuation models. Cautious scenario ¥4.10, optimistic scenario ¥7.77. It is a calculation from audited fundamentals, not an analyst target.
What is the Wuhan Hiteck Biological Pharma Co Ltd stock forecast for 2026?
Our models put fair value at ¥6.22, about −76% upside versus the last price from Sep 30, 2026 of ¥25.54 (overvalued). Cautious scenario ¥4.10, optimistic scenario ¥7.77. The calculation is refreshed regularly with new filings.
What is the revenue of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Wuhan Hiteck Biological Pharma Co Ltd reported trailing-twelve-month revenue of about 492M CNY (latest available figure, as of Oct 2, 2026).
Does Wuhan Hiteck Biological Pharma Co Ltd pay a dividend?
Wuhan Hiteck Biological Pharma Co Ltd currently shows a dividend yield of about 0.53% relative to its recent price (as of Oct 2, 2026).
What is the intrinsic value of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Wuhan Hiteck Biological Pharma Co Ltd it is ¥6.22 per share (as of Oct 2, 2026), against a price of ¥25.54. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Wuhan Hiteck Biological Pharma Co Ltd stock overvalued or undervalued in 2026?
As of Oct 2, 2026, 300683 trades above its calculated fair value: price ¥25.54, fair value ¥6.22, a gap of about −76% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 300683?
No. The price is what the market pays today (¥25.54); the fair value is what the company's own numbers justify (¥6.22). For Wuhan Hiteck Biological Pharma Co Ltd the two are ¥19.32 per share apart. That gap is exactly why we show both numbers side by side.
How much is Wuhan Hiteck Biological Pharma Co Ltd worth?
The market values Wuhan Hiteck Biological Pharma Co Ltd at about 3.3B CNY (market capitalisation, as of Oct 2, 2026). Per share that is ¥25.54; our models calculate a fair value of ¥6.22 per share.
What do the bullish and bearish scenarios say about 300683?
Our models span a range for Wuhan Hiteck Biological Pharma Co Ltd: cautious scenario ¥4.10, base ¥6.22, optimistic ¥7.77 per share (as of Oct 2, 2026, price ¥25.54). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Balance-sheet figures for Wuhan Hiteck Biological Pharma Co Ltd (as of Oct 2, 2026): return on equity −12.4%, debt of 0.01 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is 300683 from its 52-week high?
Wuhan Hiteck Biological Pharma Co Ltd trades at ¥25.54, about 48% below its 52-week high of ¥48.78 and 12% above the low of ¥22.76 (as of Sep 30, 2026). Distance from the high says nothing about value: that is what the fair value of ¥6.22 is for.
Which stocks are comparable to Wuhan Hiteck Biological Pharma Co Ltd?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries Limited, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Wuhan Hiteck Biological Pharma Co Ltd stock attractive at the current price?
The data as of Oct 2, 2026: price ¥25.54, calculated fair value ¥6.22 (−76%), Quality Score 44/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 300683 calculated?
We run Wuhan Hiteck Biological Pharma Co Ltd through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥6.22, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.4 % above its aggregate fair value. Wuhan Hiteck Biological Pharma Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The latest price we hold is from Sep 30, 2026 and stands at ¥25.54. Our model-based fair value is ¥6.22, about −76% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Wuhan Hiteck Biological Pharma Co Ltd right now?
The price sits above even our optimistic bull case (¥7.77). The favourable scenario is already priced in. Weak quality (44/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (¥4.10 to ¥7.77) leaves room in how you read the outcome.
Key figures of Wuhan Hiteck Biological Pharma Co Ltd
How large is the market capitalisation of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The market capitalisation of Wuhan Hiteck Biological Pharma Co Ltd is 3.3B CNY (≈ $499M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The price-to-sales ratio of Wuhan Hiteck Biological Pharma Co Ltd is 6.80 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Earnings per share at Wuhan Hiteck Biological Pharma Co Ltd are ¥−2.07. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The dividend yield of Wuhan Hiteck Biological Pharma Co Ltd is 0.5%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The net margin of Wuhan Hiteck Biological Pharma Co Ltd is −42.7% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The return on equity (ROE) of Wuhan Hiteck Biological Pharma Co Ltd is −12.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
On an EBIT basis the return on assets of Wuhan Hiteck Biological Pharma Co Ltd is −2.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Wuhan Hiteck Biological Pharma Co Ltd (300683)?
The operating margin of Wuhan Hiteck Biological Pharma Co Ltd is −108% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Revenue at Wuhan Hiteck Biological Pharma Co Ltd is growing −43.9% versus a year earlier (3y avg −7.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Wuhan Hiteck Biological Pharma Co Ltd (300683)?
Earnings per share at Wuhan Hiteck Biological Pharma Co Ltd are growing −57.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Wuhan Hiteck Biological Pharma Co Ltd (300683) generate?
The free cash flow of Wuhan Hiteck Biological Pharma Co Ltd is −127M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Wuhan Hiteck Biological Pharma Co Ltd (300683) hold?
Wuhan Hiteck Biological Pharma Co Ltd holds more cash than debt, 395M CNY net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed
Watch Wuhan Hiteck Biological Pharma Co Ltd in the live analysis
One click puts Wuhan Hiteck Biological Pharma Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
